6533b86ffe1ef96bd12cd118
RESEARCH PRODUCT
PD-8 Regorafenib with TAS-102 in metastatic colorectal cancer patients who progressed after at least two standard therapies: Efficacy and safety results of a multicenter phase I study (REMETY)
Joerg TrojanH. SchroederJens U. MarquardtMarkus MoehlerM. A. WoernsArndt WeinmannA. KaratasJulia QuiddeAlexander SteinOliver WaidmannM. Mänzsubject
Oncologymedicine.medical_specialtyColorectal cancerbusiness.industryHematologymedicine.diseasePhase i studychemistry.chemical_compoundOncologychemistryInternal medicineRegorafenibmedicinebusinessyear | journal | country | edition | language |
---|---|---|---|---|
2020-07-01 | Annals of Oncology |